Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joe A. Tran is active.

Publication


Featured researches published by Joe A. Tran.


Bioorganic & Medicinal Chemistry | 2008

Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists

Chen Chen; Fabio C. Tucci; Wanlong Jiang; Joe A. Tran; Beth A. Fleck; Sam R.J. Hoare; Jenny Wen; Takung Chen; Michael Johns; Stacy Markison; Alan C. Foster; Dragan Marinkovic; Caroline W. Chen; Melissa Arellano; John Harman; John Saunders; Haig Bozigian; Daniel L. Marks

A series of 2-piperazine-alpha-isopropylbenzylamine derivatives were synthesized and characterized as melanocortin-4 receptor (MC4R) antagonists. Attaching an amino acid to benzylamines 7 significantly increased their binding affinity, and the resulting compounds 8-12 bound selectively to MC4R over other melanocortin receptor subtypes and behaved as functional antagonists. These compounds were also studied for their permeability using Caco-2 cell monolayers and metabolic stability in human liver microsomes. Most compounds exhibited low permeability and high efflux ratio possibly due to their high molecular weights. They also showed moderate metabolic stability which might be associated with their moderate to high lipophilicity. Pharmacokinetic properties of these MC4R antagonists, including brain penetration, were studied in mice after oral and intravenous administrations. Two compounds identified to possess high binding affinity and selectivity, 10d and 11d, were studied in a murine cachexia model. After intraperitoneal (ip) administration of 1mg/kg dose, mice treated with 10d had significantly more food intake and weight gain than the control animals, demonstrating efficacy by blocking the MC4 receptor. Similar in vivo effects were also observed when 11d was dosed orally at 20mg/kg. These results provide further evidence that a potent and selective MC4R antagonist has potential in the treatment of cancer cachexia.


Bioorganic & Medicinal Chemistry Letters | 2008

Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.

Junko Tamiya; Brian Dyck; Mingzhu Zhang; Kasey Phan; Beth A. Fleck; Anna Aparicio; Florence Jovic; Joe A. Tran; Troy Vickers; Jonathan Grey; Alan C. Foster; Chen Chen

A series of milnacipran analogs were synthesized and studied as monoamine transporter inhibitors, and several potent compounds with moderate lipophilicity were identified from the 1S,2R-isomers. Thus, 15l exhibited IC(50) values of 1.7nM at NET and 25nM at SERT, which were, respectively, 20- and 13-fold more potent than 1S,2R-milnacipran 1-II.


Bioorganic & Medicinal Chemistry Letters | 2008

Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors.

Mingzhu Zhang; Florence Jovic; Troy Vickers; Brian Dyck; Junko Tamiya; Jonathan Grey; Joe A. Tran; Beth A. Fleck; Rebecca R. Pick; Alan C. Foster; Chen Chen

Compounds with various activities and selectivities were discovered through structure-activity relationship studies of bicifadine analogs as monoamine transporter inhibitors. The norepinephrine-selective 2-thienyl compound S-6j was efficacious in a rodent pain model.


Bioorganic & Medicinal Chemistry Letters | 2008

Design and synthesis of 3-arylpyrrolidine-2-carboxamide derivatives as melanocortin-4 receptor ligands.

Joe A. Tran; Fabio C. Tucci; Melissa Arellano; Wanlong Jiang; Caroline W. Chen; Dragan Marinkovic; Beth A. Fleck; Jenny Wen; Alan C. Foster; Chen Chen

Based on 3-phenylpropionamides, a series of 3-arylpyrrolidine-2-carboxamide derivatives was designed and synthesized to study the effect of cyclizations as melanocortin-4 receptor ligands. It was found that the 2R,3R-pyrrolidine isomer possessed the most potent affinity among the four stereoisomers.


Journal of Medicinal Chemistry | 2008

Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.

Brian Dyck; Junko Tamiya; Florence Jovic; Rebecca R. Pick; Margaret J. Bradbury; Julie A. O'Brien; Jenny Wen; Michael Johns; Ajay Madan; Beth A. Fleck; Alan C. Foster; Bin-Feng Li; Mingzhu Zhang; Joe A. Tran; Troy Vickers; Jonathan Grey; John Saunders; Chen Chen

Thien-2-yl 1S,2R-milnacipran analogues were synthesized and characterized as norepinephrine/serotonin transporter inhibitors. These compounds possessed higher potencies than 1S,2R-milnacipran (2R-1) while maintaining low molecular weight and moderate lipophilicity, which are the important features for the pharmacological and pharmacokinetic characteristics of milnacipran (1). Thus, compound 5c exhibited IC50 values of 2.3 and 32 nM, respectively, at NET and SERT, which were more than 10-fold better than those of 1 (NET IC50 = 77 nM, SERT IC50 = 420 nM). Moreover, 5c achieved the same efficacy as 1, but with much lower doses, in a rodent spinal nerve ligation pain model. In addition, 5c displayed desirable pharmacokinetic properties in several species, including high oral availability and significant brain penetration.


Bioorganic & Medicinal Chemistry Letters | 2012

Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: Identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia

Satheesh B. Ravula; Jinghua Yu; Joe A. Tran; Melissa Arellano; Fabio C. Tucci; Wilna J. Moree; Bin-Feng Li; Robert E. Petroski; Jianyun Wen; Siobhan Malany; Samuel R.J. Hoare; Ajay Madan; Paul D. Crowe; Graham Beaton

The structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles, 2-morpholine and 2-thiomorpholin-2-yl-1H-benzimidazoles are described. In the lead optimization process, the pK(a) and/or logP of benzimidazole analogs were reduced either by attachment of polar substituents to the piperidine nitrogen or incorporation of heteroatoms into the piperidine heterocycle. Compounds 9a and 9b in the morpholine series and 10g in the thiomorpholine series demonstrated improved selectivity and CNS profiles compared to lead compound 2 and these are potential candidates for evaluation as sedative hypnotics.


Medicinal Chemistry | 2008

Studies on the Structure-Activity Relationship of the Basic Amine of Phenylpiperazines as Melanocortin-4 Receptor Antagonists

Chen Chen; Joe A. Tran; Melissa Arellano; Beth A. Fleck; Joseph Pontillo; Dragan Marinkovic; Fabio C. Tucci; Jenny Wen; John Saunders

A series of piperazinephenethylamines were synthesized to study the contribution of a basic amine to binding affinity at the melanocortin-4 receptor. Several potent compounds from this series possessed subnanomolar K(i) values in a competition binding assay.


Bioorganic & Medicinal Chemistry Letters | 2008

Structure–activity relationship studies on a series of piperazinebenzylalcohols and their ketone and amine analogs as melanocortin-4 receptor ligands

Dragan Marinkovic; Fabio C. Tucci; Joe A. Tran; Beth A. Fleck; Jenny Wen; Chen Chen

A series of piperazinebenzylalcohols were prepared and studied to compare with their ketone and amine analogs as MC4R antagonists. Several benzylalcohols such as 14a and 14g displayed low nanomolar binding affinities (K(i)<10 nM), and high selectivities over other melanocortin receptor subtypes.


Journal of Medicinal Chemistry | 2004

4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a Potent and Selective Melanocortin-4 Receptor AntagonistDesign, Synthesis, and Characterization

Chen Chen; Joseph Pontillo; Beth A. Fleck; Yinghong Gao; Jenny Wen; Joe A. Tran; Fabio C. Tucci; Dragan Marinkovic; and Alan C. Foster; John Saunders


Bioorganic & Medicinal Chemistry Letters | 2005

Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines.

Fabio C. Tucci; Nicole S. White; Stacy Markison; Margaret Joppa; Joe A. Tran; Beth A. Fleck; Ajay Madan; Brian Dyck; Jessica Parker; Joseph Pontillo; L. Melissa Arellano; Dragan Marinkovic; Wanlong Jiang; Caroline W. Chen; Kathleen Gogas; Val S. Goodfellow; John Saunders; Alan C. Foster; Chen Chen

Collaboration


Dive into the Joe A. Tran's collaboration.

Top Co-Authors

Avatar

Chen Chen

Neurocrine Biosciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jenny Wen

Neurocrine Biosciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge